Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Did Big Pharma Earnings Say About China Growth?

This article was originally published in PharmAsia News

Executive Summary

Moving from a mixed to a more pessimistic outlook, top executives at multinational drug firms see China as fast losing its shine, despite the country continuing to lead growth in the emerging markets. PharmAsia News has combed through quarterly earnings reports to bring you the winners, laggards and most successful growth strategies in this increasingly challenging market.

You may also be interested in...



China Pediatric Slowdown Prompts Abbott Caution

Slowing growth in China, particularly in some consumer sectors, has prompted words of caution from Abbott over the outlook for the remainder of the year, although its CEO remains positive on this key emerging market.

Bounce Or More Bumps? New China Market Data Offer Bit Of Both

Two new sets of data on growth in China’s turbulent pharma sector paint a mixed and complex picture, indicating both challenges and opportunities ahead for multinational and domestic firms in the country.

Innovation-Friendly? Cases Indicate How Far China's Willing To Protect Patents

Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel